Monitoring of safety and effectiveness of cladribine in multiple sclerosis patients over 50 years.
Age
Cladribine
Lymphocyte counts
Safety
Journal
Multiple sclerosis and related disorders
ISSN: 2211-0356
Titre abrégé: Mult Scler Relat Disord
Pays: Netherlands
ID NLM: 101580247
Informations de publication
Date de publication:
Feb 2022
Feb 2022
Historique:
received:
18
12
2021
accepted:
01
01
2022
pubmed:
11
1
2022
medline:
3
3
2022
entrez:
10
1
2022
Statut:
ppublish
Résumé
Clinical trial data regarding efficacy and safety of cladribine in MS are limited to young individuals, and the overall risk-benefit profile does not necessarily applies to elderly patients. We investigated effectiveness and safety outcomes in MS patients initiating cladribine at ≥50 years (n=35) and <50 years (n=62), over a median follow-up of 12.4 months. There were no differences in time to evidence of disease activity (HR=0.73, 95%CI=0.18-2.91, p=0.657), post-treatment lymphocyte counts (β=0.24, p=0.825) or occurrence of adverse events (OR=0.84, 95%CI=0.24-2.93, p=0.791) between age groups. Female sex and greater disability were associated with higher risk of adverse events (especially infections). These limited data do not suggest safety concerns regarding use of cladribine in elderly MS.
Identifiants
pubmed: 35007823
pii: S2211-0348(22)00005-0
doi: 10.1016/j.msard.2022.103490
pii:
doi:
Substances chimiques
Immunosuppressive Agents
0
Cladribine
47M74X9YT5
Types de publication
Letter
Langues
eng
Sous-ensembles de citation
IM
Pagination
103490Informations de copyright
Copyright © 2022. Published by Elsevier B.V.